Feasibility and Utility of a Panel Testing for 114 Cancer-associated Genes in a Clinical Setting: A Hospital-based Study

Overview

Journal Cancer Sci

Specialty Oncology

Date 2019 Feb 12

PMID 30742731

Citations 171

Authors

Kuniko Sunami

Hitoshi Ichikawa

Takashi Kubo

Mamoru Kato

Yutaka Fujiwara

Akihiko Shimomura

Takafumi Koyama

Hiroki Kakishima

Mayuko Kitami

Hiromichi Matsushita

Eisaku Furukawa

Daichi Narushima

Momoko Nagai

Hirokazu Taniguchi

Noriko Motoi

Shigeki Sekine

Akiko Maeshima

Taisuke Mori

Reiko Watanabe

Masayuki Yoshida

Akihiko Yoshida

Hiroshi Yoshida

Kaishi Satomi

Aoi Sukeda

Taiki Hashimoto

Toshio Shimizu

Satoru Iwasa

Kan Yonemori

Ken Kato

Chigusa Morizane

Chitose Ogawa

Noriko Tanabe

Kokichi Sugano

Nobuyoshi Hiraoka

Kenji Tamura

Teruhiko Yoshida

Yasuhiro Fujiwara

Atsushi Ochiai

Noboru Yamamoto

Takashi Kohno

Affiliations

Soon will be listed here.

Abstract

Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital-based prospective study (TOP-GEAR project, 2nd stage) to investigate the feasibility and utility of NGS-based analysis of 114 cancer-associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer-related societies. Twenty-five (13.3%) cases have since received molecular-targeted therapy according to their gene aberrations. These results indicate the utility of tumor-profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry (UMIN 000011141).

Citing Articles

Clinical utility of comprehensive genomic profiling for advanced pancreatic cancer: insights from real-world data analysis.

So E, Hayashi H, Shimozaki K, Horie S, Kishimoto S, Chida A Int J Clin Oncol. 2025; .

PMID: 39961905 DOI: 10.1007/s10147-025-02713-5.

Real-world data analysis for factors influencing the quality check status in FoundationOne CDx cancer genomic profiling tests.

Niitsu H, Nakahara H, Ishida K, Kaneko Y, Hayes C, Arihiro K Sci Rep. 2025; 15(1):5167.

PMID: 39939621 PMC: 11822185. DOI: 10.1038/s41598-025-85846-x.

-Mutated Lung Adenocarcinoma With Li-Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report.

Fujii H, Okuma Y, Hirata M, Shinno Y, Yoshida T, Goto Y JTO Clin Res Rep. 2025; 6(2):100691.

PMID: 39906181 PMC: 11791262. DOI: 10.1016/j.jtocrr.2024.100691.

Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan.

Noguchi T, Ariga S, Moku R, Kikuchi J, Amano T, Maeda T JCO Precis Oncol. 2025; 9():e2400437.

PMID: 39823560 PMC: 11753464. DOI: 10.1200/PO-24-00437.

Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes.

Yamaguchi K, Tsuchihashi K, Ueno S, Uehara K, Taguchi R, Ito M ESMO Open. 2025; 10(1):104108.

PMID: 39765187 PMC: 11758824. DOI: 10.1016/j.esmoop.2024.104108.

References

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Li H, Durbin R . Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010; 26(5):589-95. PMC: 2828108. DOI: 10.1093/bioinformatics/btp698. View

Chakradhar S . Tumor sequencing takes off, but insurance reimbursement lags. Nat Med. 2014; 20(11):1220-1. DOI: 10.1038/nm1114-1220. View

Kou T, Kanai M, Yamamoto Y, Kamada M, Nakatsui M, Sakuma T . Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors. Cancer Sci. 2017; 108(7):1440-1446. PMC: 5497931. DOI: 10.1111/cas.13265. View

Kato M, Nakamura H, Nagai M, Kubo T, Elzawahry A, Totoki Y . A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing. Genome Med. 2018; 10(1):44. PMC: 5992758. DOI: 10.1186/s13073-018-0547-0. View

Oye K, Eichler H, Hoos A, Mori Y, Mullin T, Pearson M . Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan. Clin Pharmacol Ther. 2016; 100(6):626-632. DOI: 10.1002/cpt.505. View

Li M, Datto M, Duncavage E, Kulkarni S, Lindeman N, Roy S . Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2016; 19(1):4-23. PMC: 5707196. DOI: 10.1016/j.jmoldx.2016.10.002. View

Honda T, Sakashita H, Masai K, Totsuka H, Motoi N, Kobayashi M . Deleterious Pulmonary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated With Usual Interstitial Pneumonia. JCO Precis Oncol. 2022; 2:1-24. DOI: 10.1200/PO.17.00301. View

10.

Schmidt C . Lack of progress in teen and young adult cancers concerns researchers, prompts study. J Natl Cancer Inst. 2006; 98(24):1760-3. DOI: 10.1093/jnci/djj517. View

11.

Landrum M, Lee J, Benson M, Brown G, Chao C, Chitipiralla S . ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2017; 46(D1):D1062-D1067. PMC: 5753237. DOI: 10.1093/nar/gkx1153. View

12.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

13.

Frampton G, Fichtenholtz A, Otto G, Wang K, Downing S, He J . Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31(11):1023-31. PMC: 5710001. DOI: 10.1038/nbt.2696. View

14.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

15.

Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A . Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 2019; 110(4):1480-1490. PMC: 6447843. DOI: 10.1111/cas.13969. View

16.

Saito M, Shimada Y, Shiraishi K, Sakamoto H, Tsuta K, Totsuka H . Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. Cancer Res. 2015; 75(11):2264-71. DOI: 10.1158/0008-5472.CAN-14-3282. View

17.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

18.

Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim H . Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017; 23(6):703-713. PMC: 5461196. DOI: 10.1038/nm.4333. View

19.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X . Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016; 534(7605):47-54. PMC: 4910866. DOI: 10.1038/nature17676. View

20.

Ogiwara H, Sasaki M, Mitachi T, Oike T, Higuchi S, Tominaga Y . Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. Cancer Discov. 2015; 6(4):430-45. DOI: 10.1158/2159-8290.CD-15-0754. View